亚临床甲状腺功能障碍症和发生性心房的治疗方法
Mohammad Jay1, Peter Huan2, Nikki Cliffe3
1Department of Medicine, Division of Endocrinology, University of Toronto, Toronto, Ontario, Canada.
Clinical endocrinology
|October 14, 2024
概括
治疗亚临床甲状腺功能障碍症 (SH) 显示了减少心房动 (AF) 发生率的趋势. 需要进一步的大规模研究来确认SH治疗是否能预防AF.
科学领域:
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
- 流行病学 流行病学
背景情况:
- 过度甲状腺功能障碍的治疗可以预防心房动 (AF).
- 亚临床甲状腺功能障碍 (SH) 与AF有关,但治疗的预防作用尚不清楚.
研究的目的:
- 调查SH治疗与新发性AF之间的关联.
- 为了确定治疗SH是否减少AF发生率.
主要方法:
- 从2000年到2021年,对成年门诊患者诊断出SH的回顾性队列研究.
- 排除标准包括先前的AF,甲状腺功能低下,甲状腺癌,下垂体疾病或怀孕.
- 对发生的AF的随访,并对心电图和心声学特征进行二次分析.
主要成果:
- 360名患者 (131名接受治疗,229名未接受治疗) 接受了平均4.27年的随访.
- 最初的分析显示,治疗组中较低的AF趋势不显著 (3.1%对6.6%).
- 在治疗开始后30天内排除AF病例的灵敏度分析显示,治疗组中减少AF发病率的显著趋势 (p=0.02).
结论:
- 在SH的治疗中,AF发病率和患病率下降的趋势被证实.
- 结果表明,SH治疗可能有助于预防AF,因此需要进行更大规模的研究.
- 在治疗和未治疗组之间没有观察到心电图或心声回声学特征的显著差异.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
918
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
918
Dysrhythmias VI: Management of Dysrhythmias
3
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
3
Disturbances in Heart Rhythm
913
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
913
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
716
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
716
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
788
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
788
Atherosclerosis III: Management
2
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
2


